Ignite Creation Date:
2025-12-24 @ 4:40 PM
Ignite Modification Date:
2026-01-04 @ 1:44 PM
Study NCT ID:
NCT02562066
Status:
COMPLETED
Last Update Posted:
2021-04-02
First Post:
2015-09-24
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
Sponsor:
Catalyst Pharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-01
Start Date Type:
None
Primary Completion Date:
2019-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-10
Completion Date Type:
ACTUAL
First Submit Date:
2015-09-24
First Submit QC Date:
None
Study First Post Date:
2015-09-29
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2021-02-08
Results First Submit QC Date:
None
Results First Post Date:
2021-04-02
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-03-08
Last Update Post Date:
2021-04-02
Last Update Post Date Type:
ACTUAL